PNKP

Across TCGA pan-cancer cohorts, PNKP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PNKP data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PNKP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PNKP expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where PNKP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.663	0.347	.016	8	view →
HNSC	OS	Median	All	0.484	1.000	.038	7	view →
PDAC	OS	Median	III,IV	0.973	0.513	.004	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	OS	Median	II,III,IV	1.000	0.909	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PNKP–LUAD (DFS)

Open the LUAD breakdown →